Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.44 |
| ▸ | METAP1 | P53582 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | METAP2 | P50579 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6566364 | 0.98 | CYP1A2 (0.48) | CYP1A2SIGMAR1METAP1MAPTMETAP2 | |
| SCHEMBL1678164 | 0.89 | — | — | |
| SCHEMBL6663470 | 0.86 | METAP1 (0.47) | CYP1A2SIGMAR1METAP1METAP2MEN1 | |
| SCHEMBL1791563 | 0.86 | METAP1 (0.47) | CYP1A2SIGMAR1METAP1METAP2MEN1 | |
| SCHEMBL13429375 | 0.86 | METAP1 (0.47) | CYP1A2SIGMAR1METAP1METAP2MEN1 | |
| SCHEMBL7272902 | 0.86 | METAP1 (0.47) | CYP1A2SIGMAR1METAP1METAP2MEN1 | |
| SCHEMBL13068702 | 0.84 | METAP1 (0.44) | CYP1A2SIGMAR1METAP1METAP2MEN1 | |
| SCHEMBL9253751 | 0.82 | CYP1A2 (0.56) | CYP1A2SIGMAR1METAP1MAPTOPRK1 | |
| SCHEMBL1524631 | 0.82 | CYP1A2 (0.56) | CYP1A2SIGMAR1METAP1MAPTOPRK1 | |
| SCHEMBL1678790 | 0.82 | MAPT (0.41) | CYP1A2SIGMAR1MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11655216-B2 | Aryl and heteroaryl ether derivatives as liver X receptor beta agonists, compositions, and their use | MERCK SHARP & DOHME LLC (US) | 2023-05-23 | — | — | US | disclosed |
| EP-1838304-B1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | SCHERING CORP (US) | 2009-08-19 | — | — | EP | disclosed |
| US-5710323-A | REACTION OF COMPOUND WITH CARBON MONOXIDE AND WATER FOR CARBOXYLATION | IDEMITSU PETROCHEMICAL CO., LTD. (JP) | 1998-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11655216-B2 | Aryl and heteroaryl ether derivatives as liver X receptor beta agonists, compositions, and their use | NR1H2, NR1H3, NR1H4 | CYP1A2 26/4885SIGMAR1 143/4885METAP1 3196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.